Previous studies showed that terazosin (TZ), an FDA-approved drug developed to treat hypertension and benign prostatic hyperplasia, has an additional target, phosphoglycerate kinase 1 (PGK1), the first ATP-generating enzyme in glycolysis (5). The gene discussed is PGK1; the disease is benign prostatic hyperplasia.